Cell-Based Assays Market Overview, Driving Factors, Key Players and Forecast Report 2024

Press Release

The global cell-based assays market size is anticipated to grow on account of rise in the incidence of chronic diseases, increasing public and private intervention in the area of research and development, inclination towards cell-based assays over traditional biochemical assays, and a sustained increase in the drug discovery activity. According to the Centers for Disease Control and Prevention, 7 out of ten causes of death were due to chronic ailments, in 2014. Additionally, the cell-based assay techniques have many advantages over conventional methodology. The continuous advancement in technological products under cell-based assay along with their cost effectiveness are the major drivers of the growth of global cell-based assays market.

The stringent intellectual property rights, the need of high skilled professionals to perform the cell-based assays processes, and the high cost of apparatus are some of the factors restraining the growth of the global cell based assay market.

Request for sample copy of this report at: https://www.psmarketresearch.com/market-analysis/cell-based-assays-market/report-sample

Geographically, North America has been the largest region in the global cell-based assays market, mainly attributable to the high public and private funding in the research and development field of cell-based assays market. North America is expected to remain the largest market in the global market during the period 2017 – 2023, followed by the Europe. Asia-Pacific is expected to witness the highest growth during the forecast period with, countries such as China, Japan and India expected to be the growing centers of the cell-based assay market in the region.

Some of the major players operating in the global cell-based assays market include Merck KGaA, Becton, Dickinson and Company, Promega Corporation, Danaher Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Cell Signaling Technology, Inc., BioTek Instruments Inc., Lonza Group, ProQinase GmbH, Charles River Laboratories Inc, Cisbio Bioassays, Miltenyi Biotec, Cell Biolabs, Inc.,  DiscoverX Corporation, BioAgilytix Labs., Enzo Life Sciences, Inc., Aurelia Bioscience Ltd., Selexis SA, and QGel SA.

This post was originally published on Financial Sector

Comments are closed.